An innovative treatment for skin cancer that merges immunotherapy with mRNA vaccine technology has shown promising outcomes in a late-phase trial, as per a joint announcement by pharmaceutical giants Merck and Moderna on Wednesday. The combined therapy, known as intismeran, outperformed standalone immunotherapy in curbing melanoma recurrence and preventing its spread in post-surgery melanoma patients.
Described as “statistically significant and clinically meaningful improvements,” the preliminary results of the Phase 3 trial, which is still ongoing, were met with cautious optimism by medical professionals. The full trial findings are set to be presented at an upcoming oncology conference and shared with regulatory bodies.
Dr. Marcus Butler, a leading oncologist at Toronto’s Princess Margaret Cancer Centre, expressed excitement over the early success, citing positive outcomes from the prior Phase 2 study. However, he emphasized the need for further validation and a potential timeline of over eight months for the treatment to become accessible in Canada.
Addressing the logistical challenges of scaling up the treatment globally, Dr. Ramy Saleh from McGill University highlighted the critical aspects of cost implications and garnering support from taxpayers and governments.
The treatment mechanism involves combining Merck’s pembrolizumab (Keytruda) immunotherapy drug with a personalized mRNA vaccine from Moderna, tailored to target specific tumor mutations in individual patients. Pembrolizumab boosts the immune response by removing inhibitory signals, while mRNA vaccines instruct cells to fight off threats like cancer cells.
Notably, the trial involved 1,137 at-risk melanoma patients, including Canadians, who received either the combined treatment or Keytruda alone. While no new safety concerns arose during the trial, concerns remain regarding the general immune-stimulating effects of mRNA vaccines and the need for distinguishing specific responses to combat melanoma.
Dr. Butler cautioned that the current trial’s scope is limited to early-stage melanoma and may not necessarily translate to success in advanced stages. Additional trials targeting later-stage melanoma are ongoing, with past studies yielding mixed results, underscoring the importance of continued research in this field.
